S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABGI
ABG Acquisition Corp. I
$10.19
$10.17
$9.73
$10.42
$196.97M-0.0284,652 shs2,100 shs
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
$10.59
+0.0%
$10.59
$10.11
$11.55
$75.59M0.0126,457 shs200 shs
Biophytis S.A. stock logo
BPTS
Biophytis
$0.28
-3.5%
$0.43
$0.27
$4.22
$4.08M1.05285,053 shs45,834 shs
PLBY Group, Inc. stock logo
PLBY
PLBY Group
$0.91
-1.1%
$0.99
$0.43
$2.01
$66.03M2.53642,464 shs197,204 shs
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$2.66
-1.5%
$4.42
$2.40
$48.79
$7.26M7.94197,999 shs30,456 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABGI
ABG Acquisition Corp. I
0.00%0.00%0.00%0.00%0.00%
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
0.00%0.00%0.00%0.00%0.00%
Biophytis S.A. stock logo
BPTS
Biophytis
-4.03%-16.72%-31.98%-50.24%-92.36%
PLBY Group, Inc. stock logo
PLBY
PLBY Group
-0.66%-14.25%+3.54%-6.03%-44.91%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-1.48%-0.75%-40.49%-60.94%-71.99%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABGI
ABG Acquisition Corp. I
N/AN/AN/AN/AN/AN/AN/AN/A
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Biophytis S.A. stock logo
BPTS
Biophytis
1.24 of 5 stars
3.53.00.00.01.20.00.6
PLBY Group, Inc. stock logo
PLBY
PLBY Group
1.774 of 5 stars
3.22.00.00.03.01.70.6
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABGI
ABG Acquisition Corp. I
N/AN/AN/AN/A
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
N/AN/AN/AN/A
Biophytis S.A. stock logo
BPTS
Biophytis
3.00
Buy$15.005,278.27% Upside
PLBY Group, Inc. stock logo
PLBY
PLBY Group
2.40
Hold$2.67193.36% Upside
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest PLBY, BPTS, VVOS, ATA, and ABGI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2024
PLBY Group, Inc. stock logo
PLBY
PLBY Group
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABGI
ABG Acquisition Corp. I
N/AN/AN/AN/A($0.30) per shareN/A
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
N/AN/A$0.14 per share77.71($0.13) per shareN/A
Biophytis S.A. stock logo
BPTS
Biophytis
N/AN/AN/AN/A($0.43) per shareN/A
PLBY Group, Inc. stock logo
PLBY
PLBY Group
$142.95M0.46N/AN/A$0.62 per share1.47
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$13.80M0.53N/AN/A$0.22 per share12.09

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABGI
ABG Acquisition Corp. I
-$740KN/A0.00N/AN/A-0.21%0.01%N/A
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
$1.96MN/A0.00N/AN/A-23.48%0.90%N/A
Biophytis S.A. stock logo
BPTS
Biophytis
-$18.43MN/A0.00N/AN/AN/AN/AN/AN/A
PLBY Group, Inc. stock logo
PLBY
PLBY Group
-$180.42M-$2.61N/AN/AN/A-119.60%-93.57%-19.31%5/8/2024 (Estimated)
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$13.58M-$11.05N/AN/A-98.42%-665.17%-122.48%6/13/2024 (Estimated)

Latest PLBY, BPTS, VVOS, ATA, and ABGI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A-$3.05-$3.05-$3.05N/A$3.25 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABGI
ABG Acquisition Corp. I
N/AN/AN/AN/AN/A
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
N/AN/AN/AN/AN/A
Biophytis S.A. stock logo
BPTS
Biophytis
N/AN/AN/AN/AN/A
PLBY Group, Inc. stock logo
PLBY
PLBY Group
N/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABGI
ABG Acquisition Corp. I
N/A
0.84
0.84
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
N/A
0.02
0.02
Biophytis S.A. stock logo
BPTS
Biophytis
N/A
0.72
0.72
PLBY Group, Inc. stock logo
PLBY
PLBY Group
4.14
1.18
0.96
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A
0.34
0.34

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ABGI
ABG Acquisition Corp. I
71.63%
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
55.60%
Biophytis S.A. stock logo
BPTS
Biophytis
0.05%
PLBY Group, Inc. stock logo
PLBY
PLBY Group
32.46%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26.35%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ABGI
ABG Acquisition Corp. I
219.33 million15.06 millionNot Optionable
Americas Technology Acquisition Corp. stock logo
ATA
Americas Technology Acquisition
N/A7.14 million5.71 millionNot Optionable
Biophytis S.A. stock logo
BPTS
Biophytis
2614.05 million13.53 millionNot Optionable
PLBY Group, Inc. stock logo
PLBY
PLBY Group
24972.64 million51.58 millionOptionable
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
1542.73 million2.47 millionOptionable

PLBY, BPTS, VVOS, ATA, and ABGI Headlines

SourceHeadline
TELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head AnalysisTELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis
americanbankingnews.com - April 15 at 6:20 AM
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Drop in Short InterestVivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Drop in Short Interest
americanbankingnews.com - April 12 at 3:04 AM
Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approvalVivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval
proactiveinvestors.com - April 11 at 3:32 PM
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical DevicesVivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
finance.yahoo.com - April 9 at 6:42 PM
Vivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral DevicesVivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral Devices
markets.businessinsider.com - April 9 at 1:41 PM
Whats Going On With Vivos Therapeutics Stock?What's Going On With Vivos Therapeutics Stock?
msn.com - April 9 at 1:41 PM
Medicare to reimburse for Vivos CARE sleep apnea devicesMedicare to reimburse for Vivos CARE sleep apnea devices
msn.com - April 9 at 1:41 PM
Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursementVivos Therapeutics CARE oral medical devices approved for Medicare reimbursement
proactiveinvestors.com - April 9 at 9:31 AM
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
investorplace.com - April 9 at 8:53 AM
Vivos Therapeutics files to sell 1.73M shares of common stock for holdersVivos Therapeutics files to sell 1.73M shares of common stock for holders
msn.com - April 9 at 8:41 AM
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
finance.yahoo.com - April 9 at 8:41 AM
Vivos Therapeutics Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementVivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
globenewswire.com - April 9 at 7:30 AM
Verve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety ReportVerve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety Report
precisionmedicineonline.com - April 2 at 5:52 PM
Vivos Therapeutics highlights path to cash flow positivity after FDA clearanceVivos Therapeutics highlights path to cash flow positivity after FDA clearance
proactiveinvestors.com - April 1 at 9:07 AM
Vivos Therapeutics Full Year 2023 Earnings: Misses ExpectationsVivos Therapeutics Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - March 31 at 1:42 PM
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call TranscriptVivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 30 at 12:38 PM
Vivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q Loss
marketwatch.com - March 29 at 1:13 AM
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
globenewswire.com - March 28 at 4:05 PM
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
globenewswire.com - March 28 at 7:30 AM
Vivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest Report
benzinga.com - February 22 at 12:09 PM
Vivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesVivos Therapeutics Stock (NASDAQ:VVOS) Insider Trades
benzinga.com - February 22 at 7:09 AM
Vivos Therapeutics secures $4 million through warrant exerciseVivos Therapeutics secures $4 million through warrant exercise
investing.com - February 18 at 12:39 AM
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
finance.yahoo.com - February 15 at 9:27 AM
Vivos Therapeutics sees gross proceeds of $4M from exercise of warrantVivos Therapeutics sees gross proceeds of $4M from exercise of warrant
proactiveinvestors.com - February 15 at 9:13 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

ABG Acquisition Corp. I

NASDAQ:ABGI
ABG Acquisition Corp. I does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ABG Acquisition Corp. I was incorporated in 2020 and is based in New York, New York.
Americas Technology Acquisition logo

Americas Technology Acquisition

NYSEARCA:ATA
Americas Technology Acquisition Corp. does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, recapitalization, reorganization, or similar business combination in the technology, media, and telecommunications sector. The company was incorporated in 2020 and is based in Dallas, Texas.
Biophytis logo

Biophytis

NASDAQ:BPTS
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
PLBY Group logo

PLBY Group

NASDAQ:PLBY
PLBY Group, Inc. operates as a pleasure and leisure company in the United States, Australia, China, the United Kingdom, and internationally. It operates through three segments: Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. The company offers sexual wellness products, such as lingerie, bedroom accessories, intimacy products, and other adult products; style and apparel products for men and women; digital entertainment and lifestyle products; and beauty and grooming products for men and women, such as skincare, haircare, bath and body, grooming, cosmetics, and fragrance. It also owns and operates digital commerce retail platforms, such as playboy.com, honeybirdette.com, yandy.com, and loversstores.com; and Honey Birdette and Lovers retail stores. In addition, the company licenses Playboy name, Rabbit Head Design, and other trademarks and related properties; and programming content to cable television operators and direct-to-home satellite television operators. Further, the company business covers the subscription sale of playboyplus.com and playboy.tv, which are online content platforms. It offers its products under its flagship brand Playboy. PLBY Group, Inc. is headquartered in Los Angeles, California.
Vivos Therapeutics logo

Vivos Therapeutics

NASDAQ:VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.